Publications by authors named "Roger Moser"

Claim this Profile
I
Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS/FTD.
Tariq Afroz, Elodie Chevalier, Mickael Audrain, Christopher Dumayne, Tamar Ziehm, Roger Moser

Neurobiol Dis· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disruptive Technologies for Achieving Supply Chain Resilience in COVID-19 Era: An Implementation Case Study of Satellite Imagery and Blockchain Technologies in Fish Supply Chain.
Tuhin Sengupta, Gopalakrishnan Narayanamurthy, Roger Moser, Vijay Pereira, Devleena Bhattacharjee

Inf Syst Front· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Access-Based Services for the Base of the Pyramid.
Tobias Schaefers, Roger Moser, Gopalakrishnan Narayanamurthy

J Serv Res· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration.
Elpida Tsika, Liliane Glauser, Roger Moser, Aris Fiser, Guillaume Daniel

Hum Mol Genet· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily.
Klodjan Stafa, Elpida Tsika, Roger Moser, Alessandra Musso, Liliane Glauser

Hum Mol Genet· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation.
Ulrike Träger, Ralph Andre, Nayana Lahiri, Anna Magnusson-Lind, Andreas Weiss, Roger Moser

Brain· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also target specific Huntington's disease-related mechanisms.
Ana Jovicic, Julien Francisco Zaldivar Jolissaint, Roger Moser, Mariana de Fatima Silva Santos, Ruth Luthi-Carter

PLoS One· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive expression analyses of neural cell-type-specific miRNAs identify new determinants of the specification and maintenance of neuronal phenotypes.
Ana Jovičić, Reema Roshan, Nicoleta Moisoi, Sylvain Pradervand, Roger Moser

J Neurosci· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition.
David M Taylor, Roger Moser, Etienne Régulier, Lionel Breuillaud, Meredith Dixon

J Neurosci· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Common pathogenic effects of missense mutations in the P-type ATPase ATP13A2 (PARK9) associated with early-onset parkinsonism.
Agata Podhajska, Alessandra Musso, Alzbeta Trancikova, Klodjan Stafa, Roger Moser

PLoS One· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The proteolytic activity of the paracaspase MALT1 is key in T cell activation.
Fabien Rebeaud, Stephan Hailfinger, Anita Posevitz-Fejfar, Myriam Tapernoux, Roger Moser

Nat Immunol· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis